Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?

References

• Kassebaum NJ , Jasrasaria R , Naghavi M , et al. A systematic analysis of global anemia burden from 1990 to 2010. Blood. 2014 Jan 30;123(5):615–624.
   PubMed Web of Science ®Google Scholar
• St Peter WL , Guo H , Kabadi S , et al. Prevalence, treatment patterns, and healthcare resource utilization in medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol. 2018 Mar 15;19(1):67.
   PubMedGoogle Scholar
• Stauffer ME , Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9(1):e84943.
   PubMed Web of Science ®Google Scholar
• Gafter-Gvili A , Schechter A , Rozen-Zvi B. Iron deficiency anemia in chronic kidney disease. Acta Haematol. 2019 Apr 10;142(1):44–50.
   PubMed Web of Science ®Google Scholar
• Keith DS , Nichols GA , Gullion CM , et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Internal Med. 2004 Mar 22;164(6):659–663.
   PubMed Web of Science ®Google Scholar
• Ryu SR , Park SK , Jung JY , et al. The prevalence and management of anemia in chronic kidney disease patients: result from the KoreaN cohort study for outcomes in patients with chronic kidney disease (KNOW-CKD). J Korean Med Sci. 2017 Feb;32(2):249–256.
   PubMed Web of Science ®Google Scholar
• Thorp ML , Johnson ES , Yang X , et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease. Nephrology. 2009 Apr;14(2):240–246.
   PubMed Web of Science ®Google Scholar
• Olmos G , Muñoz-Félix JM , Mora I , et al. Impaired erythropoietin synthesis in chronic kidney disease is caused by alterations in extracellular matrix composition. J Cell Mol Med. 2018;22(1):302–314.
   PubMed Web of Science ®Google Scholar
• Mikhail A , Brown C , Williams JA , et al. Renal association clinical practice guideline on anaemia of chronic kidney disease. BMC Nephrol. 2017 Nov 30;18(1):345.
   PubMedGoogle Scholar
• Zumbrennen-Bullough K , Babitt JL . The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients. Nephrol Dial Transplant. 2014;29(2):263–273.
   PubMed Web of Science ®Google Scholar
• Horl WH . Non-erythropoietin-based anaemia management in chronic kidney disease. Nephrol Dial Transplant. 2002;17(Suppl 11):35–38.
   PubMedGoogle Scholar
• Macdougall IC . Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions. Clin Kidney J. 2017 Dec;10(Suppl 1):i16–i24.
   PubMedGoogle Scholar
• Levin A . Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007 Feb;22(2):309–312.
   PubMed Web of Science ®Google Scholar
• Aapro M , Gascon P , Patel K , et al. Erythropoiesis-stimulating agents in the management of anemia in chronic kidney disease or cancer: a historical perspective. Front Pharmacol. 2018;9:1498.
   PubMed Web of Science ®Google Scholar
• FDA . Drug safety communication: modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. 2017.
   Google Scholar
• Kuo KL , Hung SC , Lin YP , et al. Intravenous ferric chloride hexahydrate supplementation induced endothelial dysfunction and increased cardiovascular risk among hemodialysis patients. PLoS One. 2012;7(12):e50295.
   PubMed Web of Science ®Google Scholar
• Bailie GR , Larkina M , Goodkin DA , et al. Data from the dialysis outcomes and practice patterns study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015 Jan;87(1):162–168.
   PubMed Web of Science ®Google Scholar
• Brookhart MA , Freburger JK , Ellis AR , et al. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013 June;24(7):1151–1158.
   PubMed Web of Science ®Google Scholar
• Rostoker G . When should iron supplementation in dialysis patients be avoided, minimized or withdrawn? Semin Dial. 2019 Jan;32(1):22–29.
   PubMed Web of Science ®Google Scholar
• Rostoker G , Vaziri ND . Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. Heliyon. 2019 July;5(7):e02045.
   PubMed Web of Science ®Google Scholar
• Macdougall IC , White C , Anker SD , et al. Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL): study design and baseline data. Am J Nephrol. 2018;48(4):260–268.
   PubMed Web of Science ®Google Scholar
• O’Lone EL , Hodson EM , Nistor I , et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2019 Feb;21(2):CD007857.
   Google Scholar
• Bhandari S , Kalra PA , Berkowitz M , et al. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol dial Transplant. 2020 Feb 12. DOI:10.1093/ndt/gfaa011
   PubMed Web of Science ®Google Scholar
• Rostoker G , Vaziri ND . Iatrogenic iron overload and its potential consequences in patients on hemodialysis. Presse Med. 2017 Dec;46(12 Pt 2):e312–e328.
   PubMed Web of Science ®Google Scholar
• Macdougall IC , Bhandari S , White C , et al. Intravenous iron dosing and infection risk in patients on hemodialysis: a prespecified secondary analysis of the PIVOTAL trial. J Am Soc Nephrol. 2020 Apr 6;31(5):1118-11273.
   PubMed Web of Science ®Google Scholar
• Macdougall IC , White C , Anker SD , et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019 Jan 31;380(5):447–458.
   PubMed Web of Science ®Google Scholar
• Coyne DW , Fishbane S . The value of intravenous iron: beyond the cave of speculation. J Am Soc Nephrol. 2020 Apr 6;31(5):896-897.
   PubMed Web of Science ®Google Scholar
• Collister D , Tangri N . Post-PIVOTAL iron dosing with maintenance hemodialysis. Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1533–1535.
   PubMed Web of Science ®Google Scholar
• Wish JB . Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006 Sep;1(Suppl 1):S4–8.
   PubMedGoogle Scholar
• D’Angelo G . Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013 Mar;48(1):10–15.
   PubMedGoogle Scholar
• Moretti D , Goede JS , Zeder C , et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood. 2015 Oct 22;126(17):1981–1989.
   PubMed Web of Science ®Google Scholar
• Blanchette NL , Manz DH , Torti FM , et al. Modulation of hepcidin to treat iron deregulation: potential clinical applications. Expert Rev Hematol. 2016;9(2):169–186.
   PubMed Web of Science ®Google Scholar
• Gupta N , Wish JB . Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017 June;69(6):815–826.
   PubMed Web of Science ®Google Scholar
• Besarab A , Provenzano R , Hertel J , et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015 Oct;30(10):1665–1673.
   PubMed Web of Science ®Google Scholar
• Besarab A , Chernyavskaya E , Motylev I , et al. Roxadustat (FG-4592): correction of anemia in incident dialysis patients. J Am Soc Nephrol. 2016 Apr;27(4):1225–1233.
   PubMed Web of Science ®Google Scholar
• Provenzano R , Besarab A , Sun CH , et al. Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016 June 6;11(6):982–991.
   PubMed Web of Science ®Google Scholar
• Pergola PE , Spinowitz BS , Hartman CS , et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016 Nov;90(5):1115–1122.
   PubMed Web of Science ®Google Scholar
• Semenza GL , Wang GL . A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;Dec;12(12):5447–5454.
   PubMed Web of Science ®Google Scholar
• Wang GL , Jiang BH , Rue EA , et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995 June 6;92(12):5510–5514.
   PubMed Web of Science ®Google Scholar
• Huang LE , Gu J , Schau M , et al. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 1998 July 7;95(14):7987–7992.
   PubMed Web of Science ®Google Scholar
• Masson N , Willam C , Maxwell PH , et al. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. Embo J. 2001 Sep 17;20(18):5197–5206.
   PubMed Web of Science ®Google Scholar
• Bianchi L , Tacchini L , Cairo G . HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res. 1999 Nov 1;27(21):4223–4227.
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP , Liu Q , Unger TL , et al. Hepatic HIF-2 regulates erythropoietic responses to hypoxia in renal anemia. Blood. 2010 Oct 21;116(16):3039–3048.
   PubMed Web of Science ®Google Scholar
• Liu Q , Davidoff O , Niss K , et al. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J Clin Invest. 2012 Dec;122(12):4635–4644.
   PubMed Web of Science ®Google Scholar
• Voit RA , Sankaran VG . Stabilizing HIF to ameliorate anemia. Cell. 2020 Jan 9;180(1):6.
   PubMed Web of Science ®Google Scholar
• Bonomini M , Del Vecchio L , Sirolli V , et al. New treatment approaches for the anemia of CKD. Am J Kidney Dis. 2016 Jan;67(1):133–142.
   PubMed Web of Science ®Google Scholar
• Stalker D , Reid S , Ramaiya A , et al. Pharmacokinetic and pharmacodynamic equivalence of epoetin hospira and epogen after single subcutaneous doses to healthy male subjects. Clin Ther. 2016 Aug;38(8):1778–1788.
   PubMed Web of Science ®Google Scholar
• Bottcher M , Lentini S , Arens ER , et al. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia. Br J Clin Pharmacol. 2018 July;84(7):1557–1565.
   PubMed Web of Science ®Google Scholar
• Panjeta M , Tahirovic I , Sofic E , et al. Interpretation of erythropoietin and haemoglobin levels in patients with various stages of chronic kidney disease. J Med Biochem. 2017 Apr;36(2):145–152.
   PubMed Web of Science ®Google Scholar
• Sanghani NS , Haase VH . Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019 July;26(4):253–266.
   PubMed Web of Science ®Google Scholar
• Del Vecchio L , Locatelli F . Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease. Expert Opin Investig Drugs. 2018 July;27(7):613–621.
   PubMed Web of Science ®Google Scholar
• Kaplan JM , Sharma N , Dikdan S . Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease. Int J Mol Sci. 2018 Jan 29;19:2.
   Web of Science ®Google Scholar
• McMahon S , Grondin F , McDonald PP , et al. Hypoxia-enhanced expression of the proprotein convertase furin is mediated by hypoxia-inducible factor-1: impact on the bioactivation of proproteins. J Biol Chem. 2005 Feb 25;280(8):6561–6569.
   PubMed Web of Science ®Google Scholar
• Erez N , Milyavsky M , Eilam R , et al. Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1alpha activation and inhibits tumor growth. Cancer Res. 2003 Dec 15;63(24):8777–8783.
   PubMed Web of Science ®Google Scholar
• Xie X , Xiao H , Ding F , et al. Over-expression of prolyl hydroxylase-1 blocks NF-kappaB-mediated cyclin D1 expression and proliferation in lung carcinoma cells. Cancer Genet. 2014 May;207(5):188–194.
   PubMed Web of Science ®Google Scholar
• Ozer A , Wu LC , Bruick RK . The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A. 2005 May 24;102(21):7481–7486.
   PubMed Web of Science ®Google Scholar
• Ryan HE , Lo J , Johnson RS . HIF-1 alpha is required for solid tumor formation and embryonic vascularization. Embo J. 1998 June 1;17(11):3005–3015.
   PubMed Web of Science ®Google Scholar
• Takeda K , Cowan A , Fong GH . Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007 Aug 14;116(7):774–781.
   PubMed Web of Science ®Google Scholar
• Holdstock L , Meadowcroft AM , Maier R , et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016 Apr;27(4):1234–1244.
   PubMed Web of Science ®Google Scholar
• Brigandi RA , Johnson B , Oei C , et al. A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial. Am J Kidney Dis. 2016 June;67(6):861–871.
   PubMed Web of Science ®Google Scholar
• Flamme I , Oehme F , Ellinghaus P , et al. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014;9(11):e111838.
   PubMed Web of Science ®Google Scholar
• Locatelli F , Fishbane S , Block GA , et al. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017;45(3):187–199.
   PubMed Web of Science ®Google Scholar
• Jaakkola P , Mole DR , Tian YM , et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001 Apr 20;292(5516):468–472.
   PubMed Web of Science ®Google Scholar
• Ivan M , Kondo K , Yang H , et al. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001 Apr 20;292(5516):464–468.
   PubMed Web of Science ®Google Scholar
• Vogel S , Wottawa M , Farhat K , et al. Prolyl hydroxylase domain (PHD) 2 affects cell migration and F-actin formation via RhoA/rho-associated kinase-dependent cofilin phosphorylation. J Biol Chem. 2010 Oct 29;285(44):33756–33763.
   PubMed Web of Science ®Google Scholar
• Lee DC , Sohn HA , Park ZY , et al. A lactate-induced response to hypoxia. Cell. 2015 Apr 23;161(3):595–609.
   PubMed Web of Science ®Google Scholar
• Epstein AC , Gleadle JM , McNeill LA , et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 2001 Oct 5;107(1):43–54.
   PubMed Web of Science ®Google Scholar
• Sulser P , Pickel C , Gunter J , et al. HIF hydroxylase inhibitors decrease cellular oxygen consumption depending on their selectivity. Faseb J. 2020 Feb;34(2):2344–2358.
   PubMed Web of Science ®Google Scholar
• Salnikow K , Donald SP , Bruick RK , et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J Biol Chem. 2004 Sep 24;279(39):40337–40344.
   PubMed Web of Science ®Google Scholar
• Joharapurkar AA , Pandya VB , Patel VJ , et al. Prolyl hydroxylase inhibitors: a breakthrough in the therapy of anemia associated with chronic diseases. J Med Chem. 2018 [cited 2018 Aug 23 ];61(16):6964–6982.
   PubMed Web of Science ®Google Scholar
• Tsukiyama F , Nakai Y , Yoshida M , et al. Gallate, the component of HIF-inducing catechins, inhibits HIF prolyl hydroxylase. Biochem Biophys Res Commun. 2006 Dec 8;351(1):234–239.
   PubMed Web of Science ®Google Scholar
• Shui YB , Arbeit JM , Johnson RS , et al. HIF-1: an age-dependent regulator of lens cell proliferation. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4961–4970.
   PubMed Web of Science ®Google Scholar
• Jeon H , Kim H , Choi D , et al. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol. 2007 June;71(6):1676–1684.
   PubMed Web of Science ®Google Scholar
• Rabinowitz MH . Inhibition of hypoxia-inducible factor prolyl hydroxylase domain oxygen sensors: tricking the body into mounting orchestrated survival and repair responses.J Med Chem. 2013 [cited 2013 Dec 12 ];56(23):9369–9402.
   PubMed Web of Science ®Google Scholar
• Chan MC , Atasoylu O , Hodson E , et al. Potent and selective triazole-based inhibitors of the hypoxia-inducible factor prolyl-hydroxylases with activity in the murine brain. PLoS One. 2015;10(7):e0132004.
   PubMed Web of Science ®Google Scholar
• Beck H , Jeske M , Thede K , et al. Discovery of molidustat (BAY 85-3934): a small-molecule oral HIF-prolyl hydroxylase (HIF-PH) inhibitor for the treatment of renal anemia. ChemMedChem. 2018 May 23;13(10):988–1003.
   PubMed Web of Science ®Google Scholar
• Poli M , Asperti M , Ruzzenenti P , et al. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol. 2014;5:86.
   PubMed Web of Science ®Google Scholar
• Schmid H , Jelkmann W . Investigational therapies for renal disease-induced anemia. Expert Opin Invest Drugs. 2016 Aug;25(8):901–916.
   PubMed Web of Science ®Google Scholar
• Ariazi JL , Duffy KJ , Adams DF , et al. Discovery and preclinical characterization of GSK1278863 (Daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia. J Pharmacol Exp Ther. 2017 Dec;363(3):336–347.
   PubMed Web of Science ®Google Scholar
• Caltabiano S , Collins J , Serbest G , et al. A randomized, placebo- and positive-controlled, single-dose, crossover thorough QT/QTc study assessing the effect of daprodustat on cardiac repolarization in healthy subjects. Clin Pharmacol Drug Dev. 2017 Nov;6(6):627–640.
   PubMed Web of Science ®Google Scholar
• Holdstock L , Cizman B , Meadowcroft AM , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J. 2019 Feb;12(1):129–138.
   PubMed Web of Science ®Google Scholar
• Meadowcroft AM , Cizman B , Holdstock L , et al. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J. 2019 Feb;12(1):139–148.
   PubMed Web of Science ®Google Scholar
• Akizawa T , Tsubakihara Y , Nangaku M , et al. Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects. Am J Nephrol. 2017;45(2):127–135.
   PubMed Web of Science ®Google Scholar
• Chen N , Hao C , Liu BC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019 July 24;381:1011-1022.
   Web of Science ®Google Scholar
• Martin ER , Smith MT , Maroni BJ , et al. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380–388.
   PubMed Web of Science ®Google Scholar
• Hara K , Takahashi N , Wakamatsu A , et al. Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects. Drug Metab Pharmacokinet. 2015 Dec;30(6):410–418.
   PubMed Web of Science ®Google Scholar
• Olson E , Demopoulos L , Haws TF , et al. Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vasc Med. 2014 Dec;19(6):473–482.
   PubMed Web of Science ®Google Scholar
• Seeley TW , Sternlicht MD , Klaus SJ , et al. Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer. Hypoxia (Auckl). 2017;5:1–9.
   PubMed Web of Science ®Google Scholar
• Besarab APR , Provenzano R , Fishbane S , et al. FG-4592 oral hypoxia-inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron. J Am Soc Nephrol. 2011;22:196A.
   Google Scholar
• Wish J . HIF stabilizers: will they have a place? ASN Kidney News. 2019;11(5):14.
   Google Scholar
• Provenzano R , Besarab A , Wright S , et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016 June;67(6):912–924.
   PubMed Web of Science ®Google Scholar
• Chen N , Hao C , Liu BC , et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med. 2019 Sep 12;381(11):1011–1022.
   PubMed Web of Science ®Google Scholar
• Liu J , Zhang A , Hayden JC , et al. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis. Pharmacol Res. 2020;155:104747.
   PubMed Web of Science ®Google Scholar
• Akizawa T , Iwasaki M , Otsuka T , et al. Roxadustat treatment of chronic kidney disease-associated anemia in Japanese patients not on dialysis: a phase 2, randomized, double-blind, placebo-controlled trial. Adv Ther. 2019 June;36(6):1438–1454.
   PubMed Web of Science ®Google Scholar
• Chen N , Hao C , Peng X , et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med. 2019 July 24;381:1001-1010.
   Web of Science ®Google Scholar
• Jia L , Dong X , Yang J , et al. Effectiveness of hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat on renal anemia in non-dialysis-dependent chronic kidney disease: a systematic review and meta-analysis. Ann Transl Med. 2019 Dec;7(23):720.
   PubMed Web of Science ®Google Scholar
• AstraZeneca . Roxadustat phase III programme pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anaemia from chronic kidney disease. [cited 2020 May 5 ]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2019/roxadustat-phase-iii-programme-pooled-analyses-showed-positive-efficacy-and-no-increased-cv-risk-in-patients-with-anaemia-from-chronic-kidney-disease.html
   Google Scholar
• Li ZL , Tu Y , Liu BC . Treatment of renal anemia with roxadustat: advantages and achievement. Kidney Dis (Basel). 2020 Mar;6(2):65–73.
   PubMed Web of Science ®Google Scholar
• Provenzano R , Fishbane S , Wei L . Pooled efficacy and cardiovascular (CV) analyses of roxadustat in the treatment of anemia in CKD patients on and not on dialysis. Abstract FR-OR131 presented at the American Society of Nephrology Kidney Week 2019; Nov 5–10; Washington (DC); 2019.
   Google Scholar
• Fishbane S , El-Shahawy M , Pecoits-Filho R , et al. ROCKIES: an international, phase 3, randomized, open-label, active-controlled study of roxadustat for anemia in dialysis-dependent CKD patients. Abstract TH-OR022 presented at American Society of Nephrology Kidney Week 2019; Nov 5–10; Washington (DC); 2019.
   Google Scholar
• Fishbane S , El-Shahawy M , Pecoits-Filho R , et al. OLYMPUS: a phase 3, randomized, double-blind, placebo-controlled, international study of roxadustat efficacy in patients with non-dialysis-dependent (NDD) CKD and anemia. Abstract TH-OR023 presented at the American Society of Nephrology Kidney Week 2019; Nov 5–10; Washington (DC); 2019.
   Google Scholar
• Coyne D , Roger SD , Shin S , et al. ANDES: a phase 3, randomized, double-blind, placebo controlled study of the efficacy and safety of roxadustat for the treatment of anemia in CKD patients not on dialysis. Abstract SA-PO228 presented at the American Society of Nephrology Kidney Week 2019; Nov 5–10; Washington (DC); 2019.
   Google Scholar
• FibroGen . Redefining how to treat anemia in chronic kidney disease. [cited 2020 Apr 20 ]. Available from: https://www.fibrogen.com/roxadustat/
   Google Scholar
• FibroGen . FibroGen announces U.S. FDA acceptance of new drug application for roxadustat for the treatment of anemia of chronic kidney disease. [cited 2020 May 5 ]. Available from: https://www.globenewswire.com/news-release/2020/02/11/1983461/0/en/FibroGen-Announces-U-S-FDA-Acceptance-of-New-Drug-Application-for-Roxadustat-for-the-Treatment-of-Anemia-of-Chronic-Kidney-Disease.html
   Google Scholar
• Shalwitz RHC , Flinn C , Shalwitz I , et al. AKB-6548, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor reduces hepcidin and ferritin while it increases reticulocyte production and total iron binding capacity in healthy adults [Abstract]. J Am Soc Nephrol. 2011;(22):45A.
   Google Scholar
• Haase VHHCS , Maroni BJ , Farzeneh-Far R , et al. Vadadustat, a novel, oral treatment for anemia of chronic kidney disease, maintains stable hemoglobin levels in dialysis patients converting from erythropoiesis-stimulating agents [Abstract]. J Am Soc Nephrol. 2016;(26):B8.
   PubMedGoogle Scholar
• Hartman C , Smith MT , Flinn C , et al. AK-6548 a new hypoxia-inducible factor prolyl hydroxylase inhibitor increases hemoglobin while decreasing ferritin in a 28-day, phase 2a dose escalation study in stage 3 and 4 chronic kidney disease patients with anemia [Abstract]. J Am Soc Nephrol. 2011;(22):435A.
   Google Scholar
• Akebia . Akebia announces positive 52-week efficacy and safety data for vadadustat from two pivotal phase 3 studies in Japanese patients with anemia due to chronic kidney disease. [cited 2020 May 5 ]. Available from: https://www.businesswire.com/news/home/20191109005033/en/Akebia-Announces-Positive-52-week-Efficacy-Safety-Data
   Google Scholar
• Akizawa T , Taguchi M , Matsuda Y , et al. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies. BMJ Open. 2019 June 14;9(6):e026602.
   PubMed Web of Science ®Google Scholar
• Macdougall IC , Akizawa T , Berns JS , et al. Effects of molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol. 2019 Jan 7;14(1):28–39.
   PubMed Web of Science ®Google Scholar
• Lentini S , van der Mey D , Kern A , et al. Absorption, distribution, metabolism and excretion of molidustat in healthy participants. Basic Clin Pharmacol Toxicol. 2020 Apr 4. DOI:10.1111/bcpt.13409
   PubMed Web of Science ®Google Scholar
• Iain C , Macdougall SL , Schmidt A , et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral HIF stabilizer molidustat in pre-dialysis patients with renal anemia. ISN World Congress of Nephrology; March 13–17; Cape Town (South Africa); 2015.
   Google Scholar
• Lentini S , Kaiser A , Kapsa S , et al. Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia. Eur J Clin Pharmacol. 2020 Feb;76(2):185–197.
   PubMed Web of Science ®Google Scholar
• Akizawa T , Macdougall IC , Berns JS , et al. Long-term efficacy and safety of molidustat for anemia in chronic kidney disease: DIALOGUE extension studies. Am J Nephrol. 2019;49(4):271–280.
   PubMed Web of Science ®Google Scholar
• Yamamoto H , Taguchi M , Matsuda Y , et al. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open. 2019 June 14;9(6):e026704.
   PubMed Web of Science ®Google Scholar
• Akizawa T , Nangaku M , Yamaguchi T , et al. A placebo-controlled, randomized trial of enarodustat in patients with chronic kidney disease followed by long-term trial. Am J Nephrol. 2019;49(2):165–174.
   PubMed Web of Science ®Google Scholar
• Akizawa T , Nangaku M , Yamaguchi T , et al. Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial. Nephron. 2019;22:1–9.
   Google Scholar
• Fukui K , Shinozaki Y , Kobayashi H , et al. JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, stabilizes HIF-alpha protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. Eur J Pharmacol. 2019 Sep 15;859:172532.
   PubMed Web of Science ®Google Scholar
• Ogoshi Y , Matsui T , Mitani I , et al. Discovery of JTZ-951: A HIF prolyl hydroxylase inhibitor for the treatment of renal anemia. ACS Med Chem Lett. 2017 Dec 14;8(12):1320–1325.
   PubMed Web of Science ®Google Scholar
• Crielaard BJ , Lammers T , Rivella S . Targeting iron metabolism in drug discovery and delivery. Nat Rev Drug Discov. 2017 June;16(6):400–423.
   PubMed Web of Science ®Google Scholar
• Kansagra KA , Parmar D , Jani RH , et al. Phase I clinical study of ZYAN1, a novel prolyl-hydroxylase (PHD) inhibitor to evaluate the safety, tolerability, and pharmacokinetics following oral administration in healthy volunteers. Clin Pharmacokinet. 2018 Jan;57(1):87–102.
   PubMed Web of Science ®Google Scholar
• Barrett TD , Palomino HL , Brondstetter TI , et al. Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078–4088.
   PubMed Web of Science ®Google Scholar